The FLT3 gene contains instructions for a protein called FLT3, which helps white blood cells grow. A mutation in this gene encourages the growth of too many abnormal white blood cells. There are two ...

The fms-like tyrosine kinase 3 (FLT3) plays an important role in both normal and malignant hematopoiesis. Activating mutations in the FLT3 receptor can be detected in approximately 30% of acute ...

Arog Pharmaceuticals presented new results from a Phase III trial at the American Society of Hematology (ASH) Annual Meeting 2025, held in Orlando, Florida and online from 6 to 9 December. The placebo ...

Patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) had a high response rate and prolonged event-free survival (EFS) following treatment with an investigational FLT3 inhibitor and ...

Acute leukemia is thought to arise from leukemic stem cells, the properties of which have only recently begun to be characterized. 8,9 FLT3 was originally identified by its expression in hematopoietic ...

Measurement of minimal residual disease (MRD) following treatment of blood cancers is recognized as an important tool for disease management, and MRD negativity is increasingly a benchmark in clinical ...

Recently, a research team led by Dr. Liu Qingsong and Dr. Liu Jing from High Magnetic Field Laboratory of the Chinese Academy of Sciences has discovered a novel FLT3-ITD mutation-selective kinase ...

Administration of the novel Flt3 inhibitor, crenolanib, in conjunction with intensive chemotherapy, results in high response rates with acceptable toxicity supporting its current evaluation in a ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...

Through a groundbreaking new gene sequencing technology, researchers have demonstrated that the gene FLT3 is a valid therapeutic target in Acute Myeloid Leukemia, AML, one of the most common types of ...

Completion of pan-Canadian Pharmaceutical Alliance (pCPA) negotiations enables public reimbursement of Vanflyta across Canada, with Quebec reimbursing Vanflyta in May 2026 Reimbursement includes use ...